Solubility

Research smarter, deliver faster.

The Solubility Company's game-changing SPA™ technology solves the current tradeoff between substance consumption and accuracy in physicochemical characterization of early-stage R&D compounds.

A significant issue for early-stage physicochemical property assessment is the low amount of available compound for physical *in vitro* screening.

The Solubility Company's proprietary SPA™ technology is the only technology that can determine high-quality solubility from only a fraction of solid compound. One milligram of sample enables 10-20 separate measurements.

The SPA™ technology generates critical solubility data in various media including aqueous buffers, organic solvents, formulation vehicles and simulated or native biological fluids. This data is further used to assist in synthesis and solid form optimization, administration route and formulation selection for animal toxicology and clinical studies, processability assessment and by indicating potential pharmacokinetic liabilities of R&D compounds.

By using The Soluibility Company's contract research services for solubility screening, your organization will gain early access to critical information, boosting the whole subsequent drug development process.



Figure 1. pH-dependent solubility profile of model compound in USP buffers and simulated biological fluids. Less than one milligram of sample, in total, was consumed in the measurements.